John shares insights into the diagnostic approach used in evaluating industry performance and company potential. He reflects on a significant healthcare investment, highlighting the challenges of acquiring an underperforming division and the strategic importance of partnerships. The discussion reveals how past deals, once valued at modest multiples, now reflect a highly competitive landscape with dramatically inflated valuations.
